- Home
- CR vs HALO Comparison
CR vs HALO Comparison
Compare CR & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | HALO |
|---|---|---|
| Founded | 1855 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.8B |
| IPO Year | 2022 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CR | HALO |
|---|---|---|
| Price | $187.59 | $68.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $223.20 | $78.18 |
| AVG Volume (30 Days) | 395.7K | ★ 1.2M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | ★ 23.96 | N/A |
| EPS | ★ 6.26 | 2.56 |
| Revenue | ★ $2,305,000,000.00 | $151,862,000.00 |
| Revenue This Year | $27.98 | $28.24 |
| Revenue Next Year | $5.76 | $12.56 |
| P/E Ratio | $30.85 | ★ $27.27 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $141.51 | $47.50 |
| 52 Week High | $214.31 | $82.22 |
Technical Indicators
Market Signals| Indicator | CR | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 55.82 |
| Support Level | $184.22 | $67.94 |
| Resistance Level | $199.08 | $71.53 |
| Average True Range (ATR) | 5.88 | 1.83 |
| MACD | 1.85 | 0.66 |
| Stochastic Oscillator | 65.00 | 75.68 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.